Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00180804 |
| Other study ID # |
05/MRE02/20 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
April 2005 |
| Est. completion date |
August 31, 2005 |
Study information
| Verified date |
October 2023 |
| Source |
Imperial College London |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
For implantation of developing conceptus, placental cells need to invade mother's uterus to
access maternal blood supply in a control manner. We have found a combination of maternal
immune genes (the KIR family) and fetal genes (HLA-C) strongly associated with pre-eclampsia
where placenta does not implant adequately. The aim of this research is to investigate these
two genes family in women suffering with recurrent miscarriages and find a possible link
between them.
Description:
Little is known about reasons for early pregnancy failures. It is believed that some
pathology leading to defective implantation of fetus in maternal uterus may lead to recurrent
early miscarriages. This project arises from previous work on pre-eclampsia where we found
combination of maternal immune genes (KIR) with their ligand (HLA-C) in the fetus was
strongly associated with the disease. We will tissue type the fetus, mother and father in
cases of unexplained miscarriages. We hope that genetic findings in recurrent miscarriage
will lead to new insights, prevention and treatment.
